Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Nalka Strukturfond AB in connection with the acquisition of Cibes
Mandate

Vinge advised Nalka Strukturfond AB in connection with the acquisition of Cibes

June 13, 2017 Banking and Finance

Vinge has advised Nalka Strukturfond AB in connection with the acquisition of CL Intressenter AB (”Cibes”) from R12 Kapital Fund I AB as well as a number of minority owners.

Cibes is a leading manufacturer of platform lifts with its base in Gävle and with global operations. The transaction is conditional upon approval by the relevant competition authorities.

Vinge’s team consisted of responsible partner Jonas Johansson and partner Peter Sundgren together with, among others, associates Johan Mattsson, Peter Issa, Andrea Ahlgren, Lova Unge, Jasmin Draszka Ali, Frida Ställborn, Ilze Lukins, Lionardo Ojeda, Fredrika Hjelmberg, Martin Boström, Grant McKelvey and Xandra Ståhlberg as well as senior counsel Qun Gu and VDR specialist Anna Hellohf. Partner Louise Brorsson Salomon together with associate Helena Håkansson provided acquisition financing advice.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025